Updates are available Correction dated 2025-04-03
Click to view Correction: https://doi.org/10.1007/s00384-025-04880-3
-
Authors
Le, Quang A.
Greene, Mallik
Gohil, Shrey
Ozbay, A. Burak
Dore, Michael
Fendrick, A. Mark
Limburg, Paul
-
Funding
Funding for this research was provided by:
Exact Sciences Corporation
- License Information
-
More Information
Article History
Accepted: 3 January 2025
First Online: 17 January 2025
Change Date: 3 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00384-025-04880-3
Declarations
:
: Retrospective analysis of this data was conducted in adherence to the Health Insurance Portability and Accountability Act (HIPAA) regulations. Due to the use of deidentified aggregate data, the study was exempt from institutional review board (IRB) review.
: Not applicable; retrospective review of deidentified data.
: Not applicable; retrospective review of deidentified data.
: QAL, MG, SG, ABO, and PL are employees of Exact Sciences Corporation and own stock/stock options. MD is an Associate Professor of Medicine at Duke University. AMF has been a consultant for AbbVie, Amgen, Centivo, Community Oncology Association, Covered California, EmblemHealth, Exact Sciences, Freedman Health, GRAIL, Harvard University, Health & Wellness Innovations, Health at Scale Technologies, MedZed, Penguin Pay, Risalto, Sempre Health, the State of Minnesota, U.S. Department of Defense, Virginia Center for Health Innovation, Wellth, and Zansors; has received research support from the Agency for Healthcare Research and Quality, Gary and Mary West Health Policy Center, Arnold Ventures, National Pharmaceutical Council, Patient-Centered Outcomes Research Institute, Pharmaceutical Research and Manufacturers of America, the Robert Wood Johnson Foundation, the State of Michigan, and the Centers for Medicare and Medicaid Services.
